London - Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, has launched Vecuronium Bromide for Injection, 10mg, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc. [1]

According to IQVIA, US sales of Vecuronium Bromide for Injection, 10mg, were approximately $6 million in the 12 months ending February 2020.

Vecuronium Bromide for Injection is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Hikma Pharmaceuticals USA Inc. was formerly known as West-Ward Pharmaceuticals Corp.

Contact:

Steve Weiss

Tel: +1 732 720 2830

(C) 2020 Electronic News Publishing, source ENP Newswire